MRK-016 | CAS#783331-24-8 | GABAA negative allosteric modulator

MedKoo Cat#: 526625 | Name: MRK-016

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MRK-016 is a selective α5 subunit-containing GABAA negative allosteric modulator that has nootropic properties. It has been found to produce rapid, ketamine-like antidepressant effects in animal models of depression.

Chemical Structure

MRK-016

CAS#783331-24-8

Theoretical Analysis

MedKoo Cat#: 526625

Name: MRK-016

CAS#: 783331-24-8

Chemical Formula: C17H20N8O2

Exact Mass: 368.1709

Molecular Weight: 368.40

Elemental Analysis: C, 55.43; H, 5.47; N, 30.42; O, 8.69

Price and Availability

Size	Price	Availability
50mg	USD 550.00	2 Weeks
100mg	USD 950.00	2 Weeks
200mg	USD 1,650.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,650.00	2 Weeks
2g	USD 5,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

MRK-016; MRK 016; MRK016.

IUPAC/Chemical Name

3-tert-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)pyrazolo(1,5-d)(1,2,4)triazine

InChi Key

QYSYOGCIDRANAR-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H20N8O2/c1-10-6-11(23-27-10)15-21-19-7-12-14(17(2,3)4)16(22-25(12)15)26-8-13-18-9-20-24(13)5/h6-7,9H,8H2,1-5H3

SMILES Code

CN1N=CN=C1COC2=NN3C(C4=NOC(C)=C4)=NN=CC3=C2C(C)(C)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

MRK-016 is a selective α5 subunit-containing GABAA negative allosteric modulator that has nootropic properties.

In vitro activity:

In vitro activity This study quantified the effects of four α5-specific inverse agonists (TB-21007, MRK-016, α5IA and L-655708) on IPSCs (inhibitory postsynaptic currents) mediated by the three isoforms. All compounds selectively inhibited IPSC amplitudes and accelerated IPSC decay rates, albeit with distinct isoform specificities. MRK-016 also significantly accelerated IPSC rise times. Reference: Neuropharmacology. 2017 Oct;125:243-253. https://pubmed.ncbi.nlm.nih.gov/28757051/

In vivo activity:

A peripheral injection of the GABA-NAM MRK-016 restored hedonic behavior and AMPA-to-NMDA ratios in wild-type mice. MRK-016 administration increased gamma power over the prefrontal cortex in wild-type mice but not α5 knockout mice, whereas ketamine promoted gamma power in both genotypes. Hedonic behavior and AMPA-to-NMDA ratios were only restored by MRK-016 in stressed wild-type mice but not α5 knockout mice. Reference: Biol Psychiatry. 2022 Aug 1;92(3):216-226. https://pubmed.ncbi.nlm.nih.gov/35120711/

Preparing Stock Solutions

The following data is based on the product molecular weight 368.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Chen X, Keramidas A, Lynch JW. Physiological and pharmacological properties of inhibitory postsynaptic currents mediated by α5β1γ2, α5β2γ2 and α5β3γ2 GABAA receptors. Neuropharmacology. 2017 Oct;125:243-253. doi: 10.1016/j.neuropharm.2017.07.027. Epub 2017 Jul 27. PMID: 28757051. 2. Troppoli TA, Zanos P, Georgiou P, Gould TD, Rudolph U, Thompson SM. Negative Allosteric Modulation of Gamma-Aminobutyric Acid A Receptors at α5 Subunit-Containing Benzodiazepine Sites Reverses Stress-Induced Anhedonia and Weakened Synaptic Function in Mice. Biol Psychiatry. 2022 Aug 1;92(3):216-226. doi: 10.1016/j.biopsych.2021.11.024. Epub 2021 Dec 15. PMID: 35120711; PMCID: PMC9198111. 3. Paine TA, Chang S, Poyle R. Contribution of GABAA receptor subunits to attention and social behavior. Behav Brain Res. 2020 Jan 27;378:112261. doi: 10.1016/j.bbr.2019.112261. Epub 2019 Sep 24. PMID: 31560920; PMCID: PMC6948928.

In vitro protocol:

In vivo protocol:

1. Troppoli TA, Zanos P, Georgiou P, Gould TD, Rudolph U, Thompson SM. Negative Allosteric Modulation of Gamma-Aminobutyric Acid A Receptors at α5 Subunit-Containing Benzodiazepine Sites Reverses Stress-Induced Anhedonia and Weakened Synaptic Function in Mice. Biol Psychiatry. 2022 Aug 1;92(3):216-226. doi: 10.1016/j.biopsych.2021.11.024. Epub 2021 Dec 15. PMID: 35120711; PMCID: PMC9198111. 2. Paine TA, Chang S, Poyle R. Contribution of GABAA receptor subunits to attention and social behavior. Behav Brain Res. 2020 Jan 27;378:112261. doi: 10.1016/j.bbr.2019.112261. Epub 2019 Sep 24. PMID: 31560920; PMCID: PMC6948928.

1: Fischell J, Van Dyke AM, Kvarta MD, LeGates TA, Thompson SM. Rapid Antidepressant Action and Restoration of Excitatory Synaptic Strength After Chronic Stress by Negative Modulators of Alpha5-Containing GABAA Receptors. Neuropsychopharmacology. 2015 Oct;40(11):2499-509. doi: 10.1038/npp.2015.112. Epub 2015 Apr 22. PubMed PMID: 25900119; PubMed Central PMCID: PMC4569955. 2: Eimerbrink MJ, White JD, Pendry RJ, Hodges SL, Sadler LN, Wiles JD, Weintraub MK, Chumley MJ, Boehm GW. Administration of the inverse benzodiazepine agonist MRK-016 rescues acquisition and memory consolidation following peripheral administration of bacterial endotoxin. Behav Brain Res. 2015 Jul 15;288:50-3. doi: 10.1016/j.bbr.2015.03.048. Epub 2015 Mar 28. PubMed PMID: 25823763. 3: Lecker I, Yin Y, Wang DS, Orser BA. Potentiation of GABAA receptor activity by volatile anaesthetics is reduced by α5GABAA receptor-preferring inverse agonists. Br J Anaesth. 2013 Jun;110 Suppl 1:i73-81. doi: 10.1093/bja/aet038. Epub 2013 Mar 27. PubMed PMID: 23535829; PubMed Central PMCID: PMC3732063. 4: Atack JR. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement. Curr Top Med Chem. 2011;11(9):1203-14. Review. PubMed PMID: 21050171. 5: Atack JR, Maubach KA, Wafford KA, O'Connor D, Rodrigues AD, Evans DC, Tattersall FD, Chambers MS, MacLeod AM, Eng WS, Ryan C, Hostetler E, Sanabria SM, Gibson RE, Krause S, Burns HD, Hargreaves RJ, Agrawal NG, McKernan RM, Murphy MG, Gingrich K, Dawson GR, Musson DG, Petty KJ. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)- pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. J Pharmacol Exp Ther. 2009 Nov;331(2):470-84. doi: 10.1124/jpet.109.157636. Epub 2009 Aug 24. PubMed PMID: 19704033. 6: Jones P, Atack JR, Braun MP, Cato BP, Chambers MS, O'Connor D, Cook SM, Hobbs SC, Maxey R, Szekeres HJ, Szeto N, Wafford KA, MacLeod AM. Pharmacokinetics and metabolism studies on (3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy) pyrazolo[1,5-d][1,2,4]triazine, a functionally selective GABA(A) alpha5 inverse agonist for cognitive dysfunction. Bioorg Med Chem Lett. 2006 Feb 15;16(4):872-5. Epub 2005 Nov 21. PubMed PMID: 16303300. 7: Chambers MS, Atack JR, Carling RW, Collinson N, Cook SM, Dawson GR, Ferris P, Hobbs SC, O'connor D, Marshall G, Rycroft W, Macleod AM. An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties. J Med Chem. 2004 Nov 18;47(24):5829-32. PubMed PMID: 15537339.